UPDATE: Cantor Fitzgerald Downgrades Sucampo Pharmaceuticals (SCMP) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sucampo Reports First Quarter 2015 Financial Results and Corporate Update
May 6, 2015 6:30 AM EDTStrong Financial Performance Driven by Continued Revenue and Sales Growth of AMITIZA
Strong Growth in Net Income and EPS
Company Confirms 2015 Earnings Guidance
Company to Host Conference Call Today at 8:30 a.m. Eastern
BETHESDA, Md., May 6, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) today reported consolidated financial results for the first quarter ended March 31, 2015.
Sucampo reported year-over-year growth of 33% to $29.5 million in total revenue, 17% to $15.7... More
